Are Chinese Oncology Trials Generalizable to Non-Chinese Patients? A Call for Systematic Evidence
Auro del Giglio, Daniel de Iracema Gomes Cubero
Abstract
China has emerged as a major producer of oncology randomized controlled trials (RCTs). Between 2008 and 2019, 751 phase II/III oncology new drug trials were conducted in China. Yet a fundamental question remains unanswered: are results from trials conducted exclusively in Chinese patients generalizable to non-Chinese populations? This question has direct implications for regulatory decisions, clinical guidelines, and patient safety worldwide.
Referências
1. Li N, Huang HY, Wu DW, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review. Lancet Oncol. 2019;20(11):e619-26. https://doi.org/10.1016/S1470-2045(19)30491-7. PMid:31674320.
2. Touma JA, McLachlan AJ, Gross AS. The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology. Transl Cancer Res. 2017;6(Suppl 10):S1558-91. https://doi.org/10.21037/tcr.2017.09.09.
3. Kyriacou NM, Gross AS, McLachlan AJ. Inter‐ethnic differences in the efficacy and safety of tyrosine kinase inhibitors used in oncology: insights from Phase 3 Clinical Trials. Clin Transl Sci. 2025;18(5):e70224. https://doi.org/10.1111/cts.70224. PMid:40296413.
4. Zhang Y, Chen D, Cheng S, et al. Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016-2021: an observational study. PLoS Med. 2023;20(12):e1004319. https://doi.org/10.1371/journal. pmed.1004319. PMid:38085706.
5. Harris J. ODAC Recommends New Trial Data of Sintilimab in US Population of Frontline NSCLC [Internet]. OncLive; 2026 [cited 2026 Jun 4]. Available from: https://www.onclive.com/view/odac-votes-against-frontline-sintilimab-chemo-for-nonsquamous-nsclc
6. Fidler B. FDA rejects Lilly and Innovent immunotherapy, sending signal to drugmakers [Internet]. BioPharma Dive;2022 [cited 2026 Jun 4]. Available from: https://www.biopharmadive.com/news/eli-lilly-innovent-sintilimab-fda-rejection-china/620942/
7. Ajani J, El Hajbi F, Cunningham D, et al. Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study. ESMO Open. 2024;9(1):102202. https://doi.org/10.1016/j.
esmoop.2023.102202. PMid:38118368.
Submetido em:
05/05/2026
Revisado em:
17/06/2026
Aceito em:
26/06/2026
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email